

SECOND REGULAR SESSION  
SENATE COMMITTEE SUBSTITUTE FOR  
**SENATE BILL NO. 953**  
99TH GENERAL ASSEMBLY

---

Reported from the Committee on Seniors, Families and Children, February 22, 2018, with recommendation that the Senate Committee Substitute do pass.

6099S.03C

ADRIANE D. CROUSE, Secretary.

---

**AN ACT**

To repeal sections 195.015 and 195.017, RSMo, and to enact in lieu thereof two new sections relating to schedules of controlled substances.

---

*Be it enacted by the General Assembly of the State of Missouri, as follows:*

Section A. Sections 195.015 and 195.017, RSMo, are repealed and two new  
2 sections enacted in lieu thereof, to be known as sections 195.015 and 195.017, to  
3 read as follows:

195.015. 1. The department of health and senior services shall administer  
2 this chapter and may add substances to the schedules after public notice and  
3 hearing. In making a determination regarding a substance, the department of  
4 health and senior services shall consider the following:

- 5 (1) The actual or relative potential for abuse;
- 6 (2) The scientific evidence of its pharmacological effect, if known;
- 7 (3) The state of current scientific knowledge regarding the substance;
- 8 (4) The history and current pattern of abuse;
- 9 (5) The scope, duration, and significance of abuse;
- 10 (6) The risk to the public health;
- 11 (7) The potential of the substance to produce psychic or physiological  
12 dependence liability; and
- 13 (8) Whether the substance is an immediate precursor of a substance  
14 already controlled under this chapter.

15 2. After considering the factors enumerated in subsection 1 of this section  
16 the department of health and senior services shall make findings with respect  
17 thereto and issue a rule controlling the substance if it finds the substance has a

**EXPLANATION—Matter enclosed in bold-faced brackets [thus] in this bill is not enacted and is intended to be omitted in the law.**

18 potential for abuse.

19           3. If the department of health and senior services designates a substance  
20 as an immediate precursor, substances which are precursors of the controlled  
21 precursor shall not be subject to control solely because they are precursors of the  
22 controlled precursor.

23           4. If any substance is designated, rescheduled, or deleted as a controlled  
24 substance under federal law and notice thereof is given to the department of  
25 health and senior services, the department of health and senior services shall  
26 similarly control the substance under this chapter [after the expiration of] **and**  
27 **shall submit emergency rules to the secretary of state under section**  
28 **536.025 within** thirty days [from] **of** publication in the federal register of a final  
29 order designating a substance as a controlled substance or rescheduling or  
30 deleting a substance, unless within that thirty-day period, the department of  
31 health and senior services objects to inclusion, rescheduling, or deletion. In that  
32 case, the department of health and senior services shall publish the reasons for  
33 objection and afford all interested parties an opportunity to be heard. At the  
34 conclusion of the hearing, the department of health and senior services shall  
35 publish its decision, which shall be final unless altered by statute. Upon  
36 publication of objection to inclusion, rescheduling or deletion under this chapter  
37 by the department of health and senior services, control under this chapter is  
38 stayed as to the substance in question until the department of health and senior  
39 services publishes its decision. **If the department promulgates emergency**  
40 **rules under this subsection, such rules may, notwithstanding the**  
41 **provisions of subsection 7 of section 536.025, remain in effect until the**  
42 **general assembly concludes its next regular session following the**  
43 **imposition of any such rules.**

44           5. The department of health and senior services shall exclude any  
45 nonnarcotic substance from a schedule if such substance may, under the federal  
46 Food, Drug, and Cosmetic Act and the law of this state, be lawfully sold over the  
47 counter without a prescription.

48           6. The department of health and senior services shall prepare a list of all  
49 drugs falling within the purview of controlled substances. Upon preparation, a  
50 copy of the list shall be filed in the office of the secretary of state.

195.017. 1. The department of health and senior services shall place a  
2 substance in Schedule I if it finds that the substance:

3           (1) Has high potential for abuse; and

4 (2) Has no accepted medical use in treatment in the United States or  
5 lacks accepted safety for use in treatment under medical supervision.

6 2. Schedule I:

7 (1) The controlled substances listed in this subsection are included in  
8 Schedule I;

9 (2) Any of the following opiates, including their isomers, esters, ethers,  
10 salts, and salts of isomers, esters, and ethers, unless specifically excepted,  
11 whenever the existence of these isomers, esters, ethers and salts is possible  
12 within the specific chemical designation:

13 (a) Acetyl-alpha-methylfentanyl (**N-(1-(1-methyl-2-phenethyl)-4-**  
14 **piperidinyl)-N-phenylacetamide**);

15 (b) Acetylmethadol;

16 (c) **Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-**  
17 **phenylacetamide**);

18 **(d) AH-7921(3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]**  
19 **benzamide**);

20 (e) Allylprodine;

21 [(d)] **(f) Alphacetylmethadol (except levoalphacetylmethadol, also**  
22 **known as levo-alpha-acetylmethadol levothadyl acetate or LAAM)**;

23 [(e)] **(g) Alphameprodine**;

24 [(f)] **(h) Alphamethadol**;

25 [(g)] **(i) Alpha-methylfentanyl (N-1-(alphamethyl-beta-phenyl) ethyl-**  
26 **4-piperidyl) propionanilide; 1-(1-methyl-2-phenylethyl)-4 ((N-**  
27 **propanilido) piperidine)**;

28 [(h)] **(j) Alpha-methylthiofentanyl (N-(1-methyl-2-(2-thienyl) ethyl-4-**  
29 **piperidinyl)-N-phenylpropanamide)**;

30 [(i)] **(k) Benzethidine**;

31 [(j)] **(l) Betacetylmethadol**;

32 [(k)] **(m) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)-4-**  
33 **piperidinyl)-N-phenylpropanamide)**;

34 [(l)] **(n) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-**  
35 **phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide)**;

36 [(m)] **(o) Betameprodine**;

37 [(n)] **(p) Betamethadol**;

38 [(o)] **(q) Betaprodine**;

39 [(p)] **(r) Clonitazene**;

- 40 [(q)] (s) Dextromoramide;
- 41 [(r)] (t) Diampromide;
- 42 [(s)] (u) Diethylthiambutene;
- 43 [(t)] (v) Difenoxin;
- 44 [(u)] (w) Dimenoxadol;
- 45 [(v)] (x) Dimepheptanol;
- 46 [(w)] (y) Dimethylthiambutene;
- 47 [(x)] (z) Dioxaphetyl butyrate;
- 48 [(y)] (aa) Dipipanone;
- 49 [(z)] (bb) Ethylmethylthiambutene;
- 50 [(aa)] (cc) Etonitazene;
- 51 [(bb)] (dd) Etoxeridine;
- 52 [(cc)] (ee) Furethidine;
- 53 [(dd)] (ff) Hydroxypethidine;
- 54 [(ee)] (gg) Ketobemidone;
- 55 [(ff)] (hh) Levomoramide;
- 56 [(gg)] (ii) Levophenacylmorphan;
- 57 [(hh)] (jj) 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4-
- 58 piperidyl)-N-phenylpropanamide), its optical and geometric isomers,
- 59 salts and salts of isomers;
- 60 [(ii)] (kk) 3-Methylthiofentanyl (N-((3-methyl-1-(2-thienyl)ethyl-4-
- 61 piperidinyl)-N-phenylpropanamide);
- 62 [(jj)] (ll) Morpheridine;
- 63 [(kk)] (mm) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 64 [(ll)] (nn) Noracymethadol;
- 65 [(mm)] (oo) Norlevorphanol;
- 66 [(nn)] (pp) Normethadone;
- 67 [(oo)] (qq) Norpipanone;
- 68 [(pp)] (rr) Para-fluorofentanyl (N-(4-fluorophenyl)-N-(1-(2-
- 69 phenethyl)-4-piperidinyl) propanamide;
- 70 [(qq)] (ss) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 71 [(rr)] (tt) Phenadoxone;
- 72 [(ss)] (uu) Phenampromide;
- 73 [(tt)] (vv) Phenomorphan;
- 74 [(uu)] (ww) Phenoperidine;
- 75 [(vv)] (xx) Piritramide;

- 76 [(ww)] (yy) Proheptazine;
- 77 [(xx)] (zz) Properidine;
- 78 [(yy)] (aaa) Propiram;
- 79 [(zz)] (bbb) Racemoramide;
- 80 [(aaa)] (ccc) Thiofentanyl (N-phenyl-N-(1-(2-thienyl)ethyl-4-
- 81 piperidinyl)-propanamide;
- 82 [(bbb)] (ddd) Tilidine;
- 83 [(ccc)] (eee) Trimeperidine;
- 84 (3) Any of the following opium derivatives, their salts, isomers and salts
- 85 of isomers unless specifically excepted, whenever the existence of these salts,
- 86 isomers and salts of isomers is possible within the specific chemical designation:
- 87 (a) Acetorphine;
- 88 (b) Acetyldihydrocodeine;
- 89 (c) Benzylmorphine;
- 90 (d) Codeine methylbromide;
- 91 (e) Codeine-N-Oxide;
- 92 (f) Cyprenorphine;
- 93 (g) Desomorphine;
- 94 (h) Dihydromorphine;
- 95 (i) Drotebanol;
- 96 (j) Etorphine (except hydrochloride salt);
- 97 (k) Heroin;
- 98 (l) Hydromorphenol;
- 99 (m) Methyldesorphine;
- 100 (n) Methyldihydromorphine;
- 101 (o) Morphine methylbromide;
- 102 (p) Morphine methylsulfonate;
- 103 (q) Morphine-N-Oxide;
- 104 (r) Myrophine;
- 105 (s) Nicocodeine;
- 106 (t) Nicomorphine;
- 107 (u) Normorphine;
- 108 (v) Pholcodine;
- 109 (w) Thebacon;
- 110 (4) Any material, compound, mixture or preparation which contains any
- 111 quantity of the following hallucinogenic substances, their salts, isomers and salts

112 of isomers, unless specifically excepted, whenever the existence of these salts,  
113 isomers, and salts of isomers is possible within the specific chemical designation:

- 114 (a) **Alpha-ethyltryptamine;**  
115 (b) 4-bromo-2, 5-dimethoxyamphetamine;  
116 [(b) 4-bromo-2, 5-dimethoxyphenethylamine;]  
117 (c) **4-Bromo-2,5-dimethoxyphenethylamine;**  
118 (d) 2,5-dimethoxyamphetamine;  
119 [(d)] (e) 2,5-dimethoxy-4-ethylamphetamine;  
120 [(e)] (f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;  
121 [(f)] (g) **2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine;**  
122 (h) **2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine;**  
123 (i) **2-(2,5-Dimethoxy-4-methylphenyl) ethanamine;**  
124 (j) **2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine;**  
125 (k) **2-(2,5-Dimethoxyphenyl) ethanamine;**  
126 (l) **2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine;**  
127 (m) **2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine;**  
128 (n) **2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine;**  
129 (o) **2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine;**  
130 (p) 4-methoxyamphetamine;  
131 [(g)] (q) 5-methoxy-3,4-methylenedioxyamphetamine;  
132 [(h)] (r) 4-methyl-2, 5-dimethoxyamphetamine;  
133 [(i)] (s) 3,4-methylenedioxyamphetamine;  
134 [(j)] (t) 3,4-methylenedioxymethamphetamine;  
135 [(k)] (u) 3,4-methylenedioxy-N-ethylamphetamine;  
136 [(l)] (v) N-hydroxy-3, 4-methylenedioxyamphetamine;  
137 [(m)] (w) 3,4,5-trimethoxyamphetamine;  
138 [(n)] (x) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine[, its isomers,  
139 salts, and salts of isomers];  
140 [(o) Alpha-ethyltryptamine;  
141 (p)] (y) Alpha-methyltryptamine;  
142 [(q)] (z) Bufotenine;  
143 [(r)] (aa) Diethyltryptamine;  
144 [(s)] (bb) Dimethyltryptamine;  
145 [(t)] (cc) 5-methoxy-N,N-diisopropyltryptamine;  
146 [(u)] (dd) Ibogaine;  
147 [(v)] (ee) Lysergic acid diethylamide;

- 148 [(w)] **(ff)** Marijuana or marihuana;
- 149 [(x)] **(gg)** Mescaline;
- 150 [(y)] **(hh)** Parahexyl;
- 151 [(z)] **(ii)** Peyote, to include all parts of the plant presently classified
- 152 botanically as *Lophophora* [Williamsil] **williamsii** Lemaire, whether growing or
- 153 not; the seeds thereof; any extract from any part of such plant; and every
- 154 compound, manufacture, salt, derivative, mixture or preparation of the plant, its
- 155 seed or extracts;
- 156 [(aa)] **(jj)** N-ethyl-3-piperidyl benzilate;
- 157 [(bb)] **(kk)** N-methyl-3-piperidyl benzilate;
- 158 [(cc)] **(ll)** Psilocybin;
- 159 [(dd)] **(mm)** Psilocyn;
- 160 [(ee)] **(nn)** Tetrahydrocannabinols naturally contained in a plant of the
- 161 genus *Cannabis* (cannabis plant), as well as synthetic equivalents of the
- 162 substances contained in the cannabis plant, or in the resinous extractives of such
- 163 plant, or synthetic substances, derivatives[,] and their isomers, **or both**, with
- 164 similar chemical structure and pharmacological activity to those substances
- 165 contained in the plant, such as the following:
- 166 a. 1 cis or trans tetrahydrocannabinol[,] and their optical isomers;
- 167 b. 6 cis or trans tetrahydrocannabinol[,] and their optical isomers;
- 168 c. 3,4 cis or trans tetrahydrocannabinol[,] and their optical isomers;
- 169 d. Any compounds of these structures, regardless of numerical designation
- 170 of atomic positions covered;
- 171 [(ff)] **(oo)** Ethylamine analog of phencyclidine;
- 172 [(gg)] **(pp)** Pyrrolidine analog of phencyclidine;
- 173 [(hh)] **(qq)** Thiophene analog of phencyclidine;
- 174 [(ii)] **(rr)** 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 175 [(jj)] **(ss)** *Salvia divinorum*;
- 176 [(kk)] **(tt)** Salvinorin A;
- 177 [(ll)] **(uu)** Synthetic cannabinoids:
- 178 a. Any compound structurally derived from 3-(1-naphthoyl)indole or
- 179 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the
- 180 indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 181 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not
- 182 further substituted in the indole ring to any extent, whether or not substituted
- 183 in the naphthyl ring to any extent. Including, but not limited to:

- 184 (i) **AM2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;**  
185 (ii) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;  
186 [(ii)] (iii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;  
187 [(iii)] (iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;  
188 [(iv)] (v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;  
189 [(v)] (vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;  
190 [(vi)] (vii) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;  
191 [(vii)] (viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;  
192 [(viii)] (ix) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;  
193 [(ix)] (x) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;  
194 [(x)] (xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;  
195 [(xi)] (xii) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;  
196 [(xii)] (xiii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;  
197 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by  
198 substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,  
199 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or  
200 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole  
201 ring to any extent, whether or not substituted in the naphthyl ring to any extent;  
202 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene  
203 by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl,  
204 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or  
205 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene  
206 ring to any extent, whether or not substituted in the naphthyl ring to any extent;  
207 d. Any compound structurally derived from 3-phenylacetylindole by  
208 substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl,  
209 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or  
210 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole  
211 ring to any extent, whether or not substituted in the phenyl ring to any  
212 extent. Including, but not limited to:  
213 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;  
214 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;  
215 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;  
216 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;  
217 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;  
218 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol  
219 by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl,



220 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or  
221 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring  
222 to any extent. Including, but not limited to:

223 (i) CP 47, 497 [ & ] **and** homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]  
224 -5-(2-methyloctan-2-yl)phenol), where side chain n=5, and homologues where side  
225 chain n-4,6, or 7;

226 f. Any compound containing a 3-(benzoyl)indole structure with  
227 substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl,  
228 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or  
229 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole  
230 ring to any extent and whether or not substituted in the phenyl ring to any  
231 extent. Including, but not limited to:

232 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;

233 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (**SR-19 and RCS-4**);

234 g. CP 50, 556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-  
235 phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

236 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-  
237 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

238 i. HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-  
239 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

240 j. [CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-  
241 phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

242 k.] Dimethylheptylpyran, or DMHP;

243 (5) Any material, compound, mixture or preparation containing any  
244 quantity of the following substances having a depressant effect on the central  
245 nervous system, including their salts, isomers and salts of isomers whenever the  
246 existence of these salts, isomers and salts of isomers is possible within the  
247 specific chemical designation:

248 (a) Gamma-hydroxybutyric acid;

249 (b) Mecloqualone;

250 (c) Methaqualone;

251 (6) Any material, compound, mixture or preparation containing any  
252 quantity of the following substances having a stimulant effect on the central  
253 nervous system, including their salts, isomers and salts of isomers:

254 (a) Aminorex;

255 (b) N-benzylpiperazine;

- 256 (c) Cathinone;
- 257 (d) Fenethylamine;
- 258 (e) 3-Fluoromethcathinone;
- 259 (f) 4-Fluoromethcathinone;
- 260 (g) Mephedrone, or 4-methylmethcathinone;
- 261 (h) Methcathinone;
- 262 (i) 4-methoxymethcathinone;
- 263 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-
- 264 oxazolamine);
- 265 (k) Methylene dioxy p y r o v a l e r o n e , M D P V , o r
- 266 (1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone;
- 267 (l) Methylone, or 3,4-Methylenedioxy methcathinone;
- 268 (m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP;
- 269 (n) N-ethylamphetamine;
- 270 (o) N,N-dimethylamphetamine;
- 271 **(p) Quinolin-8-yl 1-pentyl-1*H*-indole-3-carboxylate (PB-22;**
- 272 **QUPIC);**
- 273 **(q) Quinolin-8-yl 1-(5-fluoropentyl)-1*H*-indole-3-carboxylate (5-**
- 274 **fluoro-PB-22; 5F-PB-22);**
- 275 **(r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1*H*-**
- 276 **indazole-3-carboxamide (AB-FUBINACA);**
- 277 **(s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-**
- 278 **indazole-3-carboxamide (ADB-PINACA);**
- 279 (7) A temporary listing of substances subject to emergency scheduling
- 280 under federal law shall include any material, compound, mixture or preparation
- 281 which contains any quantity of the following substances:
- 282 (a) [N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its
- 283 optical isomers, salts and salts of isomers;
- 284 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
- 285 (thenylfentanyl), its optical isomers, salts and salts of isomers;] **(1-pentyl-1*H*-**
- 286 **indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, its optical,**
- 287 **positional, and geometric isomers, salts, and salts of isomers;**
- 288 **(b) [1-(5-fluoro-pentyl)-1*H*-indol-3-yl](2,2,3,3-**
- 289 **tetramethylcyclopropyl)methanone, its optical, positional, and**
- 290 **geometric isomers, salts, and salts of isomers;**
- 291 **(c) N-(1-adamantyl)-1-pentyl-1*H*-indazole-3-carboxamide, its**

- 292 optical, positional, and geometric isomers, salts, and salts of isomers;  
293 (d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-  
294 methoxybenzyl)ethanamine, its optical, positional, and geometric  
295 isomers, salts, and salts of isomers;
- 296 (e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-  
297 methoxybenzyl)ethanamine, its optical, positional, and geometric  
298 isomers, salts, and salts of isomers;
- 299 (f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-  
300 methoxybenzyl)ethanamine, its optical, positional, and geometric  
301 isomers, salts, and salts of isomers;
- 302 (g) 4-methyl-N-ethylcathinone, its optical, positional, and  
303 geometric isomers, salts, and salts of isomers;
- 304 (h) 4-methyl-alpha-pyrrolidinopropiophenone, its optical,  
305 positional, and geometric isomers, salts, and salts of isomers;
- 306 (i) Alpha-pyrrolidinopentiophenone, its optical, positional, and  
307 geometric isomers, salts, and salts of isomers;
- 308 (j) Butylone, its optical, positional, and geometric isomers, salts,  
309 and salts of isomers;
- 310 (k) Pentedrone, its optical, positional, and geometric isomers,  
311 salts, and salts of isomers;
- 312 (l) Pentylone, its optical, positional, and geometric isomers, salts,  
313 and salts of isomers;
- 314 (m) Naphyrone, its optical, positional, and geometric isomers,  
315 salts, and salts of isomers;
- 316 (n) Alpha-pyrrolidinobutiophenone, its optical, positional, and  
317 geometric isomers, salts, and salts of isomers;
- 318 (o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-  
319 indazole-3-carboxamide, its optical, positional, and geometric isomers,  
320 salts, and salts of isomers;
- 321 (p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-  
322 carboxamide, its optical, positional, and geometric isomers, salts, and  
323 salts of isomers;
- 324 (q) [1-(5-fluoropentyl)-1*H*-indazole-3-yl](naphthalen-1-  
325 yl)methanone, its optical, positional, and geometric isomers, salts, and  
326 salts of isomers;
- 327 (r) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its  
328 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

329 (s) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin-4-yl]-N-  
330 phenylpropionamide, its isomers, esters, ethers, salts, and salts of  
331 isomers, esters, and ethers;

332 (t) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its optical,  
333 positional, and geometric isomers, salts, and salts of isomers;

334 (u) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-  
335 (cyclohexylmethyl)-1*H*-indazole-3-carboxamide, its optical, positional,  
336 and geometric isomers, salts, and salts of isomers;

337 (v) 3, 4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-  
338 methylbenzamide;

339 (w) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide;

340 (x) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3,3-  
341 dimethylbutanoate, its optical, positional, and geometric isomers, salts,  
342 and salts of isomers;

343 (y) methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3-  
344 methylbutanoate, its optical, positional, and geometric isomers, salts,  
345 and salts of isomers;

346 (z) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1*H*-indazole-3-  
347 carboxamide, its optical, positional, and geometric isomers, salts, and  
348 salts of isomers;

349 (aa) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-  
350 1*H*-indazole-3-carboxamide, its optical, positional, and geometric  
351 isomers, salts, and salts of isomers;

352 (bb) methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-  
353 carboxamido)-3,3-dimethylbutanoate, its optical, positional, and  
354 geometric isomers, salts, and salts of isomers;

355 (cc) methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3,3-  
356 dimethylbutanoate, its optical, positional, and geometric isomers, salts,  
357 and salts of isomers;

358 (dd) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)  
359 isobutyramide, its isomers, esters, ethers, salts, and salts of isomers,  
360 esters, and ethers;

361 (ee) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, its  
362 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

363 (ff) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-  
364 yl)propionamide, its isomers, esters, ethers, salts, and salts of isomers,  
365 esters, and ethers;

- 366 (gg) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-  
367 carboxamide, its isomers, esters, ethers, salts, and salts of isomers,  
368 esters, and ethers;
- 369 (hh) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,  
370 its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
- 371 (ii) Methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3-  
372 methylbutanoate, its optical, positional, and geometric isomers, salts,  
373 and salts of isomers;
- 374 (jj) N-(1-phenethylpiperidin-4-yl)-N-  
375 phenylcyclopropanecarboxamide, its isomers, esters, ethers, salts, and  
376 salts of isomers, esters, and ethers;
- 377 (kk) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide, its  
378 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
- 379 (ll) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide,  
380 its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
- 381 (mm) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-  
382 yl)butyramide, its isomers, esters, ethers, salts, and salts of isomers,  
383 esters, and ethers;
- 384 (nn) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-  
385 yl)isobutyramide, its isomers, esters, ethers, salts, and salts of isomers,  
386 esters, and ethers;
- 387 (oo) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide, its  
388 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
- 389 (pp) N-(1-phenethylpiperidin-4-yl)-N-  
390 phenylcyclopentanecarboxamide, its isomers, esters, ethers, salts, and  
391 salts of isomers, esters, and ethers;
- 392 (qq) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-  
393 yl)acetamide, its isomers, esters, ethers, salts, and salts of isomers,  
394 esters, and ethers;
- 395 (rr) Fentanyl-related substances, their isomers, esters, ethers,  
396 salts, and salts of isomers, esters, and ethers. Fentanyl-related  
397 substance shall mean any substance not otherwise listed under another  
398 Drug Enforcement Administration Controlled Substance Code Number,  
399 and for which no exemption or approval is in effect under section 505  
400 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. Section 355, that  
401 is structurally related to fentanyl by one or more of the following  
402 modifications:

403           a. **Replacement of the phenyl portion of the phenethyl group by**  
404 **an monocycle, whether or not further substituted in or on the**  
405 **monocycle;**

406           b. **Substitution in or on the phenethyl group with alkyl, alkenyl,**  
407 **alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups;**

408           c. **Substitution in or on the piperidine ring with alkyl, alkenyl,**  
409 **alkoxyl, ester, ether, hydroxyl, amino or nitro groups;**

410           d. **Replacement of the aniline ring with any aromatic monocycle,**  
411 **whether or not further substituted in or on the aromatic monocycle; or**

412           e. **Replacement of the N-propionyl group by another acyl group;**

413           (8) Khat, to include all parts of the plant presently classified botanically  
414 as catha edulis, whether growing or not; the seeds thereof; any extract from any  
415 part of such plant; and every compound, manufacture, salt, derivative, mixture,  
416 or preparation of the plant, its seed or extracts.

417           3. The department of health and senior services shall place a substance  
418 in Schedule II if it finds that:

419           (1) The substance has high potential for abuse;

420           (2) The substance has currently accepted medical use in treatment in the  
421 United States, or currently accepted medical use with severe restrictions; and

422           (3) The abuse of the substance may lead to severe psychic or physical  
423 dependence.

424           4. The controlled substances listed in this subsection are included in  
425 Schedule II:

426           (1) Any of the following substances whether produced directly or indirectly  
427 by extraction from substances of vegetable origin, or independently by means of  
428 chemical synthesis, or by combination of extraction and chemical synthesis:

429           (a) Opium and opiate; and any salt, compound, derivative or preparation  
430 of opium or opiate, excluding apomorphine, thebaine-derived butorphanol,  
431 dextrorphan, nalbuphine, nalmefene, **naloxegol**, naloxone, and naltrexone, and  
432 their respective salts but including the following:

433           a. Raw opium;

434           b. Opium extracts;

435           c. Opium fluid;

436           d. Powdered opium;

437           e. Granulated opium;

438           f. Tincture of opium;

- 439 g. Codeine;
- 440 h. **Dihydroetorphine;**
- 441 i. Ethylmorphine;
- 442 [i.] j. Etorphine hydrochloride;
- 443 [j.] k. Hydrocodone;
- 444 [k.] l. Hydromorphone;
- 445 [l.] m. Metopon;
- 446 [m.] n. Morphine;
- 447 [n.] o. **Oripavine;**
- 448 p. Oxycodone;
- 449 [o.] q. Oxymorphone;
- 450 [p.] r. Thebaine;
- 451 (b) Any salt, compound, derivative, or preparation thereof which is
- 452 chemically equivalent or identical with any of the substances referred to in this
- 453 subdivision, but not including the isoquinoline alkaloids of opium;
- 454 (c) Opium poppy and poppy straw;
- 455 (d) Coca leaves and any salt, compound, derivative, or preparation of coca
- 456 leaves, and any salt, compound, derivative, or preparation thereof which is
- 457 chemically equivalent or identical with any of these substances, but not including
- 458 **the following:**
- 459 a. Decocainized coca leaves or extractions **of coca leaves**, which
- 460 **extractions** do not contain cocaine or ecgonine; **or**
- 461 **b. Ioflupane;**
- 462 (e) Concentrate of poppy straw (the crude extract of poppy straw in either
- 463 liquid, solid or powder form which contains the phenanthrene alkaloids of the
- 464 opium poppy);
- 465 (2) Any of the following opiates, including their isomers, esters, ethers,
- 466 salts, and salts of isomers, whenever the existence of these isomers, esters,
- 467 ethers, and salts is possible within the specific chemical designation, dextrorphan
- 468 and levopropoxyphene excepted:
- 469 (a) Alfentanil;
- 470 (b) Alphaprodine;
- 471 (c) Anileridine;
- 472 (d) Bezitramide;
- 473 (e) Bulk dextropropoxyphene;
- 474 (f) Carfentanil;

- 475 (g) Dihydrocodeine;
- 476 (h) Diphenoxylate;
- 477 (i) Fentanyl;
- 478 (j) Isomethadone;
- 479 (k) Levo-alphaacetylmethadol;
- 480 (l) Levomethorphan;
- 481 (m) Levorphanol;
- 482 (n) Metazocine;
- 483 (o) Methadone;
- 484 (p) [Meperidine];
- 485 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl
- 486 butane;
- 487 [(r)] (q) Moramide-Intermediate, 2-methyl-3-morpholino-1,
- 488 1-diphenylpropane-carboxylic acid;
- 489 [(s)] (r) Pethidine (meperidine);
- 490 [(t)] (s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 491 [(u)] (t) P e t h i d i n e - I n t e r m e d i a t e - B ,
- 492 ethyl-4-phenylpiperidine-4-carboxylate;
- 493 [(v)] (u) P e t h i d i n e - I n t e r m e d i a t e - C ,
- 494 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 495 [(w)] (v) Phenazocine;
- 496 [(x)] (w) Piminodine;
- 497 [(y)] (x) Racemethorphan;
- 498 [(z)] (y) Racemorphan;
- 499 [(aa)] (z) Remifentanyl;
- 500 [(bb)] (aa) Sufentanyl;
- 501 [(cc)] (bb) Tapentadol;
- 502 (cc) **Thiafentanyl**;
- 503 (3) Any material, compound, mixture, or preparation which contains any
- 504 quantity of the following substances having a stimulant effect on the central
- 505 nervous system:
- 506 (a) Amphetamine, its salts, optical isomers, and salts of its optical
- 507 isomers;
- 508 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
- 509 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 510 (d) Phenmetrazine and its salts;



511 (e) Methylphenidate;  
512 (4) Any material, compound, mixture, or preparation which contains any  
513 quantity of the following substances having a depressant effect on the central  
514 nervous system, including its salts, isomers, and salts of isomers whenever the  
515 existence of those salts, isomers, and salts of isomers is possible within the  
516 specific chemical designation:

517 (a) Amobarbital;

518 (b) Glutethimide;

519 (c) Pentobarbital;

520 (d) Phencyclidine;

521 (e) Secobarbital;

522 (5) [Any material or compound which contains any quantity of nabilone]

523 **Hallucinogenic substances:**

524 (a) **Any material or compound which contains any quantity of**  
525 **nabilone;**

526 (b) **Dronabinol [(-)- $\Delta$ -9-trans tetrahydrocannabinol] in an oral**  
527 **solution in a drug product approved for marketing by the U.S. Food and**  
528 **Drug Administration;**

529 (6) Any material, compound, mixture, or preparation which contains any  
530 quantity of the following substances:

531 (a) Immediate precursor to amphetamine and methamphetamine:  
532 Phenylacetone;

533 (b) Immediate precursors to phencyclidine (PCP):

534 a. 1-phenylcyclohexylamine;

535 b. 1-piperidinocyclohexanecarbonitrile (PCC);

536 (c) **Immediate precursor to fentanyl: 4-anilino-N-phenethyl-4-**  
537 **piperidine (ANPP);**

538 (7) Any material, compound, mixture, or preparation which contains any  
539 quantity of the following alkyl nitrites:

540 (a) Amyl nitrite;

541 (b) Butyl nitrite.

542 5. The department of health and senior services shall place a substance  
543 in Schedule III if it finds that:

544 (1) The substance has a potential for abuse less than the substances listed  
545 in Schedules I and II;

546 (2) The substance has currently accepted medical use in treatment in the

547 United States; and

548 (3) Abuse of the substance may lead to moderate or low physical  
549 dependence or high psychological dependence.

550 6. The controlled substances listed in this subsection are included in  
551 Schedule III:

552 (1) Any material, compound, mixture, or preparation which contains any  
553 quantity of the following substances having a potential for abuse associated with  
554 a stimulant effect on the central nervous system:

- 555 (a) Benzphetamine;
- 556 (b) Chlorphentermine;
- 557 (c) Clortermine;
- 558 (d) Phendimetrazine;

559 (2) Any material, compound, mixture or preparation which contains any  
560 quantity or salt of the following substances or salts having a depressant effect on  
561 the central nervous system:

562 (a) Any material, compound, mixture or preparation which contains any  
563 quantity or salt of the following substances combined with one or more active  
564 medicinal ingredients:

- 565 a. Amobarbital;
- 566 b. Secobarbital;
- 567 c. Pentobarbital;

568 (b) Any suppository dosage form containing any quantity or salt of the  
569 following:

- 570 a. Amobarbital;
- 571 b. Secobarbital;
- 572 c. Pentobarbital;

573 (c) Any substance which contains any quantity of a derivative of  
574 barbituric acid or its salt;

- 575 (d) Chlorhexadol;
- 576 (e) Embutramide;

577 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers  
578 contained in a drug product for which an application has been approved under  
579 Section 505 of the federal Food, Drug, and Cosmetic Act;

- 580 (g) Ketamine, its salts, isomers, and salts of isomers;
- 581 (h) Lysergic acid;
- 582 (i) Lysergic acid amide;

- 583 (j) Methyprylon;
- 584 (k) **Perampanel, and its salts, isomers, and salts of isomers;**
- 585 **(l)** Sulfondiethylmethane;
- 586 [(l)] **(m)** Sulfonethylmethane;
- 587 [(m)] **(n)** Sulfonmethane;
- 588 [(n)] **(o)** Tiletamine and zolazepam or any salt thereof;
- 589 (3) Nalorphine;
- 590 (4) Any material, compound, mixture, or preparation containing limited
- 591 quantities of any of the following narcotic drugs or their salts:
- 592 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not
- 593 more than ninety milligrams per dosage unit, with an equal or greater quantity
- 594 of an isoquinoline alkaloid of opium;
- 595 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not
- 596 more than ninety milligrams per dosage unit, with one or more active,
- 597 nonnarcotic ingredients in recognized therapeutic amounts;
- 598 (c) [Not more than three hundred milligrams of hydrocodone per one
- 599 hundred milliliters or not more than fifteen milligrams per dosage unit, with a
- 600 fourfold or greater quantity of an isoquinoline alkaloid of opium;
- 601 (d) Not more than three hundred milligrams of hydrocodone per one
- 602 hundred milliliters or not more than fifteen milligrams per dosage unit, with one
- 603 or more active nonnarcotic ingredients in recognized therapeutic amounts;
- 604 (e)] Not more than 1.8 grams of dihydrocodeine per one hundred milliliters
- 605 or not more than ninety milligrams per dosage unit, with one or more active,
- 606 nonnarcotic ingredients in recognized therapeutic amounts;
- 607 [(f)] **(d)** Not more than three hundred milligrams of ethylmorphine per
- 608 one hundred milliliters or not more than fifteen milligrams per dosage unit, with
- 609 one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
- 610 [(g)] **(e)** Not more than five hundred milligrams of opium per one
- 611 hundred milliliters or per one hundred grams or not more than twenty-five
- 612 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
- 613 recognized therapeutic amounts;
- 614 [(h)] **(f)** Not more than fifty milligrams of morphine per one hundred
- 615 milliliters or per one hundred grams, with one or more active, nonnarcotic
- 616 ingredients in recognized therapeutic amounts;
- 617 (5) Any material, compound, mixture, or preparation containing any of the
- 618 following narcotic drugs or their salts[, as set forth in subdivision (6) of this

619 subsection;]: Buprenorphine;

620 (6) Anabolic steroids. Any drug or hormonal substance, chemically and  
621 pharmacologically related to testosterone (other than estrogens, progestins,  
622 corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except  
623 an anabolic steroid which is expressly intended for administration through  
624 implants to cattle or other nonhuman species and which has been approved by  
625 the Secretary of Health and Human Services for that administration. If any  
626 person prescribes, dispenses, or distributes such steroid for human use, such  
627 person shall be considered to have prescribed, dispensed, or distributed an  
628 anabolic steroid within the meaning of this subdivision. Unless specifically  
629 excepted or unless listed in another schedule, any material, compound, mixture  
630 or preparation containing any quantity of the following substances, including its  
631 salts, esters and ethers:

632 (a) [3 $\beta$ ,17-dihydroxy-5 $\alpha$ -androsterane] **3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androsterane;**

633 (b) 3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androsterane;

634 (c) 5 $\alpha$ -androsteran-3,17-dione;

635 (d) 1-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androster-1-ene);

636 (e) 1-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androster-1-ene);

637 (f) 4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxy-androster-4-ene);

638 (g) 5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxy-androster-5-ene);

639 (h) 1-androstenedione ([5 $\alpha$ ]-androster-1-en-3,17-dione);

640 (i) 4-androstenedione (androster-4-en-3,17-dione);

641 (j) 5-androstenedione (androster-5-en-3,17-dione);

642 (k) Bolasterone (7 $\alpha$ , 17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandroster-4-en-3-one);

643 (l) Boldenone (17 $\beta$ -hydroxyandroster-1,4,-diene-3-one);

644 (m) Boldione (**androster-1,4-diene-3,17-dione**);

645 (n) Calusterone (7 $\beta$ , 17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandroster-4-en-3-one);

646 (o) Clostebol (4-chloro-17 $\beta$ -hydroxyandroster-4-en-3-one);

647 (p) Dehydrochloromethyltestosterone (4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methyl-  
648 androster-1,4-dien-3-one);

649 (q) Desoxymethyltestosterone (**17 $\alpha$ -methyl-5 $\alpha$ -androster-2-en-17 $\beta$ -ol**)  
650 (**a.k.a. madol**);

651 (r)  $\Delta$ 1-dihydrotestosterone (a.k.a. '1-testosterone')(17 $\beta$ -hydroxy-5 $\alpha$ -androster-  
652 1-en-3-one);

653 (s) [4-dihydrotestosterone (17 $\beta$ -hydroxy-androsteran-3-one);

654 (t)] Drostanolone (17 $\beta$ -hydroxy-2 $\alpha$ -methyl-5 $\alpha$ -androsteran-3-one);

- 655 [(u)] (t) Ethylestrenol (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-ene);
- 656 [(v)] (u) Fluoxymesterone (9-fluoro-17 $\alpha$ -methyl-11 $\beta$ ,17 $\beta$ -dihydroxyandrost-  
657 4-en-3-one);
- 658 [(w)] (v) Formebolone (2-formyl-17 $\alpha$ -methyl-11 $\alpha$ ,17 $\beta$ -dihydroxyandrost-  
659 1,4-dien-3-one);
- 660 [(x)] (w) Furazabol (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrostano[2,3-c]-furazan);
- 661 [(y)] (x) 13 $\beta$ -ethyl-17 $\beta$ -hydroxygon-4-en-3-one;
- 662 [(z)] (y) 4-hydroxytestosterone (4,17 $\beta$ -dihydroxy-androst-4-en-3-one);
- 663 [(aa)] (z) 4-hydroxy-19-nortestosterone (4,17 $\beta$ -dihydroxy-estr-4-en-3-one);
- 664 [(bb)] (aa) Mestanolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5-androstan-3-one);
- 665 [(cc)] (bb) [Mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-3-one)]  
666 **Mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-3-one);**
- 667 [(dd)] (cc) Methandienone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-dien-3-  
668 one);
- 669 [(ee)] (dd) Methandriol (17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-ene);
- 670 [(ff)] (ee) **Methasterone (2 $\alpha$ ,17 $\alpha$ -dimethyl-5 $\alpha$ -androstan-17 $\beta$ -ol-3-  
671 one);**
- 672 (ff) Methenolone (1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one);
- 673 (gg) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstan-3-one);
- 674 (hh) 17 $\alpha$ -methyl-3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstan-3-one);
- 675 (ii) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene;
- 676 (jj) 17 $\alpha$ -methyl-4-hydroxynandrolone (17 $\alpha$ -methyl-4-hydroxy-17 $\beta$ -  
677 hydroxyestr-4-en-3-one);
- 678 (kk) Methyldienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9(10)-dien-3-one);
- 679 (ll) [Methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9,11-trien-3-one)]  
680 **Methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9,11-trien-3-one);**
- 681 (mm) Methyltestosterone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 682 (nn) Mibolerone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- 683 (oo) 17 $\alpha$ -methyl- $\Delta$ 1-dihydrotestosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -  
684 androst-1-en-3-one) (a.k.a. '17- $\alpha$ -methyl-1-testosterone');
- 685 (pp) Nandrolone (17 $\beta$ -hydroxyestr-4-ene-3-one);
- 686 (qq) 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-ene);
- 687 (rr) 19-nor-4-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-4-ene);
- 688 (ss) 19-nor-4,9(10)-androstadienedione (**estra-4,9(10)-diene-3,17-dione**);
- 689 (tt) 19-nor-5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-5-ene);
- 690 (uu) 19-nor-5-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-5-ene);

- 691 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);  
692 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);  
693 (xx) Norbolethone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4-en-3-one);  
694 (yy) Norclostebol (4-chloro-17 $\beta$ -hydroxyestr-4-en-3-one);  
695 (zz) Norethandrolone (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
696 (aaa) Normethandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
697 (bbb) Oxandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-2-oxa-[5 $\alpha$ ]-androstan-3-one);  
698 (ccc) Oxymesterone (17 $\alpha$ -methyl-4,17 $\beta$ -dihydroxyandrost-4-en-3-one);  
699 (ddd) Oxymethalone (17 $\alpha$ -methyl-2-hydroxymethylene-17 $\beta$ -hydroxy-[5 $\alpha$ ]-  
700 androstan-3-one);  
701 (eee) **Prostanozolol (17 $\beta$ -hydroxy-5 $\alpha$ -androstan[3,2-c]pyrazole);**  
702 **(fff) Stanolone ( $\Delta$ 1-dihydrotestosterone (a.k.a. 1-**  
703 **testosterone)(17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one));**  
704 **(ggg) Stanozolol (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androst-2-eno[3,2-c]-**  
705 **pyrazole);**  
706 [(fff)] **(hhh) Stenbolone (17 $\beta$ -hydroxy-2-methyl-[5 $\alpha$ ]-androst-1-en-3-one);**  
707 [(ggg)] **(iii) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-**  
708 **17-oic acid lactone);**  
709 [(hhh)] **(jjj) Testosterone (17 $\beta$ -hydroxyandrost-4-en-3-one);**  
710 [(iii)] **(kkk) Tetrahydrogestrinone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-**  
711 **4,9,11-trien-3-one);**  
712 [(jjj)] **(lll) Trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one);**  
713 [(kkk)] **(mmm) Any salt, ester, or ether of a drug or substance described**  
714 **or listed in this subdivision, except an anabolic steroid which is expressly**  
715 **intended for administration through implants to cattle or other nonhuman species**  
716 **and which has been approved by the Secretary of Health and Human Services for**  
717 **that administration;**  
718 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin  
719 capsule in a United States Food and Drug Administration approved drug product;  
720 (8) The department of health and senior services may except by rule any  
721 compound, mixture, or preparation containing any stimulant or depressant  
722 substance listed in subdivisions (1) and (2) of this subsection from the application  
723 of all or any part of sections 195.010 to 195.320 if the compound, mixture, or  
724 preparation contains one or more active medicinal ingredients not having a  
725 stimulant or depressant effect on the central nervous system, and if the  
726 admixtures are included therein in combinations, quantity, proportion, or

727 concentration that vitiate the potential for abuse of the substances which have  
728 a stimulant or depressant effect on the central nervous system.

729 7. The department of health and senior services shall place a substance  
730 in Schedule IV if it finds that:

731 (1) The substance has a low potential for abuse relative to substances in  
732 Schedule III;

733 (2) The substance has currently accepted medical use in treatment in the  
734 United States; and

735 (3) Abuse of the substance may lead to limited physical dependence or  
736 psychological dependence relative to the substances in Schedule III.

737 8. The controlled substances listed in this subsection are included in  
738 Schedule IV:

739 (1) Any material, compound, mixture, or preparation containing any of the  
740 following narcotic drugs or their salts calculated as the free anhydrous base or  
741 alkaloid, in limited quantities as set forth below:

742 (a) Not more than one milligram of difenoxin and not less than twenty-five  
743 micrograms of atropine sulfate per dosage unit;

744 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,  
745 2-diphenyl-3-methyl-2-propionoxybutane);

746 (c) **2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol,**  
747 **its salts, optical and geometric isomers, and salts of these isomers**  
748 **(including tramadol);**

749 (d) Any of the following limited quantities of narcotic drugs or their salts,  
750 which shall include one or more nonnarcotic active medicinal ingredients in  
751 sufficient proportion to confer upon the compound, mixture or preparation  
752 valuable medicinal qualities other than those possessed by the narcotic drug  
753 alone:

754 a. Not more than two hundred milligrams of codeine per one hundred  
755 milliliters or per one hundred grams;

756 b. Not more than one hundred milligrams of dihydrocodeine per one  
757 hundred milliliters or per one hundred grams;

758 c. Not more than one hundred milligrams of ethylmorphine per one  
759 hundred milliliters or per one hundred grams;

760 (2) Any material, compound, mixture or preparation containing any  
761 quantity of the following substances, including their salts, isomers, and salts of

762 isomers whenever the existence of those salts, isomers, and salts of isomers is  
763 possible within the specific chemical designation:

- 764 (a) **Alfaxalone**;  
765 (b) Alprazolam;  
766 [(b)] (c) Barbitol;  
767 [(c)] (d) Bromazepam;  
768 [(d)] (e) Camazepam;  
769 [(e)] (f) **Carisoprodol**;  
770 (g) Chloral betaine;  
771 [(f)] (h) Chloral hydrate;  
772 [(g)] (i) Chlordiazepoxide;  
773 [(h)] (j) Clobazam;  
774 [(i)] (k) Clonazepam;  
775 [(j)] (l) Clorazepate;  
776 [(k)] (m) Clotiazepam;  
777 [(l)] (n) Cloxazolam;  
778 [(m)] (o) Delorazepam;  
779 [(n)] (p) Diazepam;  
780 [(o)] (q) Dichloralphenazone;  
781 [(p)] (r) Estazolam;  
782 [(q)] (s) Ethchlorvynol;  
783 [(r)] (t) Ethinamate;  
784 [(s)] (u) Ethyl loflazepate;  
785 [(t)] (v) Fludiazepam;  
786 [(u)] (w) Flunitrazepam;  
787 [(v)] (x) Flurazepam;  
788 [(w)] (y) Fospropofol;  
789 [(x)] (z) Halazepam;  
790 [(y)] (aa) Haloxazolam;  
791 [(z)] (bb) Ketazolam;  
792 [(aa)] (cc) Loprazolam;  
793 [(bb)] (dd) Lorazepam;  
794 [(cc)] (ee) Lormetazepam;  
795 [(dd)] (ff) Mebutamate;  
796 [(ee)] (gg) Medazepam;  
797 [(ff)] (hh) Meprobamate;



798 [(gg)] **(ii)** Methohexital;  
799 [(hh)] **(jj)** Methylphenobarbital (mephobarbital);  
800 [(ii)] **(kk)** Midazolam;  
801 [(jj)] **(ll)** Nimetazepam;  
802 [(kk)] **(mm)** Nitrazepam;  
803 [(ll)] **(nn)** Nordiazepam;  
804 [(mm)] **(oo)** Oxazepam;  
805 [(nn)] **(pp)** Oxazolam;  
806 [(oo)] **(qq)** Paraldehyde;  
807 [(pp)] **(rr)** Petrichloral;  
808 [(qq)] **(ss)** Phenobarbital;  
809 [(rr)] **(tt)** Pinazepam;  
810 [(ss)] **(uu)** Prazepam;  
811 [(tt)] **(vv)** Quazepam;  
812 [(uu)] **(ww)** **Suvorexant**;  
813 **(xx)** Temazepam;  
814 [(vv)] **(yy)** Tetrazepam;  
815 [(ww)] **(zz)** Triazolam;  
816 [(xx)] **(aaa)** Zaleplon;  
817 [(yy)] **(bbb)** Zolpidem;  
818 [(zz)] **(ccc)** Zopiclone;

819 (3) Any material, compound, mixture, or preparation which contains any  
820 quantity of the following substance, including its salts, isomers and salts of  
821 isomers whenever the existence of such salts, isomers and salts of isomers is  
822 possible: fenfluramine;

823 (4) **Any material, compound, mixture, or preparation which**  
824 **contains any quantity of the following substances, including its salts,**  
825 **isomers, and salts of isomers, whenever the existence of such salts,**  
826 **isomers, and salts of isomers is possible: Lorcaserin;**

827 (5) Any material, compound, mixture or preparation containing any  
828 quantity of the following substances having a stimulant effect on the central  
829 nervous system, including their salts, isomers and salts of isomers:

- 830 (a) Cathine ((+)-norpseudoephedrine);  
831 (b) Diethylpropion;  
832 (c) Fencamfamin;  
833 (d) Fenproporex;

- 834 (e) Mazindol;
- 835 (f) Mefenorex;
- 836 (g) Modafinil;
- 837 (h) Pemoline, including organometallic complexes and chelates thereof;
- 838 (i) Phentermine;
- 839 (j) Pipradrol;
- 840 (k) Sibutramine;
- 841 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
- 842 [(5)] (6) Any material, compound, mixture or preparation containing any
- 843 quantity of the following substance, including its salts:
- 844 (a) Butorphanol (**including its optical isomers**);
- 845 (b) **Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-**
- 846 **dimethylphenyl]-1-oxopropyl] [(1S)-1-(4-phenyl-1 *H*-imidazol-2-**
- 847 **yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical**
- 848 **isomers) and its salts, isomers, and salts of isomers;**
- 849 (c) Pentazocine;
- 850 [(6)] (7) Ephedrine, its salts, optical isomers and salts of optical isomers,
- 851 when the substance is the only active medicinal ingredient;
- 852 [(7)] (8) The department of health and senior services may except by rule
- 853 any compound, mixture, or preparation containing any depressant substance
- 854 listed in subdivision (1) of this subsection from the application of all or any part
- 855 of sections 195.010 to 195.320 and sections 579.015 to 579.086 if the compound,
- 856 mixture, or preparation contains one or more active medicinal ingredients not
- 857 having a depressant effect on the central nervous system, and if the admixtures
- 858 are included therein in combinations, quantity, proportion, or concentration that
- 859 vitiate the potential for abuse of the substances which have a depressant effect
- 860 on the central nervous system.
- 861 9. The department of health and senior services shall place a substance
- 862 in Schedule V if it finds that:
- 863 (1) The substance has low potential for abuse relative to the controlled
- 864 substances listed in Schedule IV;
- 865 (2) The substance has currently accepted medical use in treatment in the
- 866 United States; and
- 867 (3) The substance has limited physical dependence or psychological
- 868 dependence liability relative to the controlled substances listed in Schedule IV.

869 10. The controlled substances listed in this subsection are included in  
870 Schedule V:

871 (1) Any compound, mixture or preparation containing any of the following  
872 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in  
873 limited quantities as set forth below, which also contains one or more nonnarcotic  
874 active medicinal ingredients in sufficient proportion to confer upon the compound,  
875 mixture or preparation valuable medicinal qualities other than those possessed  
876 by the narcotic drug alone:

877 (a) **Not more than two hundred milligrams of codeine per one**  
878 **hundred milliliters or per one hundred grams;**

879 (b) **Not more than one hundred milligrams of dihydrocodeine per**  
880 **one hundred milliliters or per one hundred grams;**

881 (c) **Not more than one hundred milligrams of ethylmorphine per**  
882 **one hundred milliliters or per one hundred grams;**

883 (d) Not more than two and five-tenths milligrams of diphenoxylate and  
884 not less than twenty-five micrograms of atropine sulfate per dosage unit;

885 [(b)] (e) Not more than one hundred milligrams of opium per one  
886 hundred milliliters or per one hundred grams;

887 [(c)] (f) Not more than five-tenths milligram of difenoxin and not less  
888 than twenty-five micrograms of atropine sulfate per dosage unit;

889 (2) Any material, compound, mixture or preparation which contains any  
890 quantity of the following substance having a stimulant effect on the central  
891 nervous system including its salts, isomers and salts of isomers: pyrovalerone;

892 (3) Any compound, mixture, or preparation containing any detectable  
893 quantity of pseudoephedrine or its salts or optical isomers, or salts of optical  
894 isomers or any compound, mixture, or preparation containing any detectable  
895 quantity of ephedrine or its salts or optical isomers, or salts of optical isomers;

896 (4) Unless specifically exempted or excluded or unless listed in another  
897 schedule, any material, compound, mixture, or preparation which contains any  
898 quantity of the following substances having a depressant effect on the central  
899 nervous system, including its salts:

900 (a) **Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-**  
901 **yl]butanamide) (also referred to as BRV; UCB-34714; Briviact);**

902 (b) **Ezogabine [N-[2-amino-4(4-fluorobenzylamino)-phenyl]-**  
903 **carbamic acid ethyl ester];**

904 (c) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-  
905 propionamide];

906 [(b)] (d) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].

907 11. If any compound, mixture, or preparation as specified in subdivision  
908 (3) of subsection 10 of this section is dispensed, sold, or distributed in a pharmacy  
909 without a prescription:

910 (1) All packages of any compound, mixture, or preparation containing any  
911 detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of  
912 optical isomers or ephedrine, its salts or optical isomers, or salts of optical  
913 isomers, shall be offered for sale only from behind a pharmacy counter where the  
914 public is not permitted, and only by a registered pharmacist or registered  
915 pharmacy technician; and

916 (2) Any person purchasing, receiving or otherwise acquiring any  
917 compound, mixture, or preparation containing any detectable quantity of  
918 pseudoephedrine, its salts or optical isomers, or salts of optical isomers or  
919 ephedrine, its salts or optical isomers, or salts of optical isomers shall be at least  
920 eighteen years of age; and

921 (3) The pharmacist, intern pharmacist, or registered pharmacy technician  
922 shall require any person, prior to such person's purchasing, receiving or otherwise  
923 acquiring such compound, mixture, or preparation to furnish suitable photo  
924 identification that is issued by a state or the federal government or a document  
925 that, with respect to identification, is considered acceptable and showing the date  
926 of birth of the person;

927 (4) The seller shall deliver the product directly into the custody of the  
928 purchaser.

929 12. Pharmacists, intern pharmacists, and registered pharmacy technicians  
930 shall implement and maintain an electronic log of each transaction. Such log  
931 shall include the following information:

932 (1) The name, address, and signature of the purchaser;

933 (2) The amount of the compound, mixture, or preparation purchased;

934 (3) The date and time of each purchase; and

935 (4) The name or initials of the pharmacist, intern pharmacist, or  
936 registered pharmacy technician who dispensed the compound, mixture, or  
937 preparation to the purchaser.

938 13. Each pharmacy shall submit information regarding sales of any  
939 compound, mixture, or preparation as specified in subdivision (3) of subsection 10

940 of this section in accordance with transmission methods and frequency  
941 established by the department by regulation;

942 14. No person shall dispense, sell, purchase, receive, or otherwise acquire  
943 quantities greater than those specified in this chapter.

944 15. All persons who dispense or offer for sale pseudoephedrine and  
945 ephedrine products in a pharmacy shall ensure that all such products are located  
946 only behind a pharmacy counter where the public is not permitted.

947 16. The penalties for a knowing or reckless violation of the provisions of  
948 subsections 11 to 15 of this section are found in section 579.060.

949 17. The scheduling of substances specified in subdivision (3) of subsection  
950 10 of this section and subsections 11, 12, 14, and 15 of this section shall not apply  
951 to any compounds, mixtures, or preparations that are in liquid or liquid-filled gel  
952 capsule form or to any compound, mixture, or preparation specified in subdivision  
953 (3) of subsection 10 of this section which must be dispensed, sold, or distributed  
954 in a pharmacy pursuant to a prescription.

955 18. The manufacturer of a drug product or another interested party may  
956 apply with the department of health and senior services for an exemption from  
957 this section. The department of health and senior services may grant an  
958 exemption by rule from this section if the department finds the drug product is  
959 not used in the illegal manufacture of methamphetamine or other controlled or  
960 dangerous substances. The department of health and senior services shall rely  
961 on reports from law enforcement and law enforcement evidentiary laboratories in  
962 determining if the proposed product can be used to manufacture illicit controlled  
963 substances.

964 19. The department of health and senior services shall revise and  
965 republish the schedules annually.

966 20. The department of health and senior services shall promulgate rules  
967 under chapter 536 regarding the security and storage of Schedule V controlled  
968 substances, as described in subdivision (3) of subsection 10 of this section, for  
969 distributors as registered by the department of health and senior services.

970 21. Logs of transactions required to be kept and maintained by this  
971 section and section 195.417 shall create a rebuttable presumption that the person  
972 whose name appears in the logs is the person whose transactions are recorded in  
973 the logs.

✓